Search Results
252 items found for "Keltic Pharma Therapeutics"
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic
- Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...
However, how these states impact GPCRs biological function and therapeutic targeting remains incompletely
- From DNA day to GPCR genomics
GPCR-targeted drugs, and the exploration of GPCRs as key regulators of physiological processes and therapeutic analysis, have facilitated drug discovery and design targeting GPCRs, leading to the development of novel therapeutics
- 📰 GPCR Weekly News, January 16 to 22, 2023
Industry News Addex Provides Corporate Update And Financial Guidance Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches
- Immunomodulatory Role of Neuropeptides in the Cornea
maintaining the homeostasis of the ocular surface, alterations in disease settings, and the possible therapeutic
- 📰 GPCR Weekly News, June 5 to 11, 2023
Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics Confo Therapeutics Enters Into Research Collaboration For GPCR-Targeting Antibody Discovery With AbCellera
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids
interacting with the Glucagon receptor (GCGR), which constitutes an important target for diabetes and obesity therapeutics
- GPCR Signaling and mTORC1 Regulation
of mTOR complex 1 (mTORC1) is typically observed in human disease and continues to be an important therapeutic
- 📰 GPCR Weekly News, February 6 to 12, 2023
IPO, raising $161M 3-drug combo leads to 'unprecedented' response in pancreatic cancer models Addex Therapeutics in ADX71149 Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics
- TRPM3 in the eye and in the nervous system - from new findings to novel mechanisms
clear picture is needed to unravel TRPM3's full potential as experimental tool, diagnostic marker and therapeutic
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
development of more personalised therapies tailored to the genetic makeup of individual patients, enhancing therapeutic that can drive the early stages of target and lead identification, combat drug resistance, and refine therapeutic
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
Currently, there is no cure for RP, and the therapeutic options are limited.
- Structural basis for receptor selectivity and inverse agonism in S1P5 receptors
Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
compartments and signaling pathways associated with GPCRs holds promise for the development of novel therapeutic Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
; understanding the role of DNAJC13 in GPCR trafficking could profoundly affect the development of therapeutic
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
These therapeutic strategies could greatly impact the treatment of CVD with unprecedented benefits which
- 📰 GPCR Weekly News, July 31 to August 6, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. Additional Chf 2.7 Million From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
years to uncover the mechanisms of disease before they can even dare to contemplate the development of therapeutic
- A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
These findings indicate the potential of inhibiting MC4R homodimerization as a therapeutic target to
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
These insights will facilitate further development of therapeutic agents targeting the DOR.Communicated
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and
- 📰 GPCR Weekly News, November 13 to 19, 2023
identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy Industry News OMass Therapeutics (ANDA) Litigation PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
It is a therapeutic target because it plays a role in thermogenesis, lipolysis, and bladder relaxation
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
consequently activated signaling pathways, and also may shed light on the development of more effective new therapeutics
- In vitro assays for the functional characterization of (psychedelic) substances at the serotonin...
their appearance on the (illicit) drug market, e.g. as new psychoactive substances, their potential therapeutic
- 📰 GPCR Weekly News, February 27 to March 5, 2023
Industry News Design Pharmaceuticals has a new website Confo Therapeutics Announces Global Licensing Antiverse raises €2.8M for its computational antibody drug discovery platform Antiverse identifies therapeutic